A week after Gilead Sciences Inc. struck out with the first Phase III data readout in non-alcoholic steatohepatitis, Intercept Pharmaceuticals Inc. reclaimed its spot as the company most likely to reach the market first in NASH by achieving a fibrosis-reduction endpoint in its Phase III REGENERATE study.
The New York-based firm saw its stock price soar quickly, then moderate throughout the day Feb